ANI Pharma (ANIP) Tops Q4 EPS Views; Issues FY15 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% as AI buildout costs, Fed rate outlook weigh
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
ANI Pharmaceuticals (ANIP) PT Lifted to $79 at Guggenheim
February 19, 2015 12:52 PM ESTGuggenheim analyst Louise Chen reiterated a Buy rating and boosted her price target on ANI Pharmaceuticals (NASDAQ: ANIP) to $79.00 (from $65.00) following Q4 results.
Chen commented, "Post ANIP's 4Q14 beat, we remain positive on ANIP shares, as we continue to believe a large... More
